Articles Tagged With:
-
Hospital Staff Often Overestimate Emergency Stroke Care Performance
Find out the consequences when staff over-estimates performance in quickly getting clotbusters to stroke patients.
-
The “Choosing Wisely”® Campaign: An Evidence-Based Review of the Recommendations: Part I
The purpose of this paper is to perform a critical review of available evidence regarding each of the 10 recommendations.
-
ECG Review: What are the Clinical Implications of this Rhythm?
This tracing was obtained from a 69-year-old woman with a long-term history of palpitations. Her symptoms had been increasing over recent weeks, in association with “chest tightness” and dizziness. Her prior medical history was benign, and she was hemodynamically stable at the time this tracing was recorded. How would you interpret this rhythm strip? What are the clinical implications of this rhythm?
-
Clinical Briefs
A closer look at non-alcoholic fatty liver disease, lifting the ban on total dietary fat, and the risks of digoxin use in AF patients.
-
Cholic Acid Capsules (Cholbam ®)
The cholic acid capsule is the first FDA-approved treatment for rare bile acid synthesis disorders.
-
Inferior Vena Cava Filters and Recurrent Pulmonary Embolism
Placement of retrievable inferior vena cava filters in individuals with concurrent deep vein thrombosis does not reduce the risk of recurrent pulmonary embolism.
-
Long-term Weight Loss Rivals Medications and Ablation for AF Rhythm Control
The authors conclude long-term sustained weight loss was possible and was associated with a significant reduction in atrial fibrillation burden.
-
Provocative Cardiovascular Testing for Everyone with Chest Pain?
ABSTRACT & COMMENTARY: Pain or not, it's hard to take money out of the medical equation.
-
Tramadol for Premature Ejaculation
On-demand doses of 25-50 mg tramadol administered 2-4 hours prior to intercourse is effective in prolonging vaginal ejaculatory latency time.
-
Predicting Which Patients with Non-alcoholic Fatty Liver Disease Will Progress
Certain non-alcoholic fatty liver disease patients have a progressive type called non-alcoholic steatohepatitis, which itself may progress to cirrhosis and hepatocellular carcinoma.